Objective
Diabetes is a major health problem in Europe. Limited availability of donor tissue restricts conventional transplant treatments. Therefore, we propose to bioengineer pancreatic islet microorgans (called pseudoislets) using glucose-responsive insulin-producing cells of differentiated stem cell origin. These microorgans should be suitable substitutes to restore the function of the destroyed pancreatic islets in a diabetic individual. The combination of the bioengineering of insulin-secreting surrogate cells with techniques for generation of a pancreatic islet microorgan represents a highly innovative experimental approach. This Cell Factory concept for an innovative insulin replacement therapy, applied to cells of human origin, can offer, due to the unlimited supply, a cure to many diabetic patients. The long-standing expertise and experience of the partners in this proposal bring together the capabilities to achieve this highly desirable goal.
Fields of science
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
30625 HANNOVER
Germany